Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Pirtobrutinib in CLL: updates from the BRUIN CLL-321 trial

Wojciech Jurczak • 11 Jun 2022
EHA 2022
Chronic Lymphocytic Leukemia Leukemia Ibrutinib Pirtobrutinib
BRUIN CLL-321

Wojciech Jurczak, MD, PhD, Jagiellonian University, Krakow, Poland, shares some insights into the BRUIN CLL-321 study (NCT04666038), evaluating the use of pirtobrutinib versus investigator’s choice for the treatment of chronic lymphocytic leukemia (CLL). Prof. Jurczak highlights the importance of Bruton’s tyrosine kinase (BTK) inhibitors in CLL treatment and the impressive tolerability and low toxicity of pirtobrutinib compared to other agents. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Wojciech Jurczak

1:35
Long-term follow-up of tafasitamab and lenalidomide in R/R DLBCL
Wojciech Jurczak • 10 Jun 2023
3:01
Updates from the BRUIN study – long-term safety of pirtobrutinib in R/R MCL
Wojciech Jurczak • 10 Jun 2023
1:49
Follow-up results of EPCORE NHL-1: subcutaneous epcoritamab in R/R LBCL
Wojciech Jurczak • 10 Jun 2023
1:05
Updates on tafasitamab for the treatment of DLBCL
Wojciech Jurczak • 11 Jun 2022

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals